Skip to main content
. Author manuscript; available in PMC: 2023 Jan 30.
Published in final edited form as: Biomed Pharmacother. 2021 Sep 24;143:112226. doi: 10.1016/j.biopha.2021.112226

Table 2.

Treatment outcomes.

Docetaxel plus lycopene (N = 13)
PSA Response (≥50% reduction in serum PSA)
Events (n) 10
Rate (%) 76.9
95% CI 46.18–94.96%
Disease control rate (%) 92.3
95% CI 63.97–99.8%
Duration of response (mo)
Median 7.3
95% CI 4.8–13.2
Progression free survival (mo)
Median 8
95% CI 5.5–14.7
Overall survival (mo)
Median 35.1
95% CI 25.8–57.8